# Ruibosi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ruibosi

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.darwincell.net
- Total disclosed funding: $42M
- Latest round: Series C (Dec 8, 2025)
- Investors on record: 8

## About

Based in Beijing, China and founded in 2016, Beijing Darwin Cell Biotechnology Co., Ltd., trading as Ruibosi, operates as a biotechnology company that focuses on cellular technology and product development. Lin Chen, CTO of the company, graduated from Tsinghua University and serves as the Secretary General of the International Society for Neuroprosthetics. The company has 6 intellectual property patents. In 2022, it was recognized as the National High-tech Enterprise. In December 2025, Ruibosi raised a series C+ funding from new investor Wuhan Optical Valley Financial Holding Group and returning investor THG Ventures.
The company's business can be divided into two categories, which are biotechnology technology and biopharmaceutical research and development. It has stem cells, ECIWEP targeted protein extraction process, and other cellular biotechnology. The biological drugs include nerve repair, cartilage repair skin hair follicle repair, and other drug research and development.
The company's revenue is primarily generated from the development and commercialization of biopharmaceuticals and biomedical consumables, particularly in neurological disease treatment, stem cell therapy, and protein polymer-based drug products.
The series C+ round of financing will be used to advance core technology research and development, accelerate the commercialization of scientific and technological achievements, and expand clinical application scenarios, further promoting the upgrading of medical science and technology.

## Funding rounds

- Series C, Dec 8, 2025 — THG Ventures, Wuhan Optical Valley Financial Holding Group
- Series C, Jul 30, 2025 — THG Ventures
- Series B, Dec 15, 2023, $14M — Taiping Guofa, Shanghai Yungu Investment
- Series A, Jan 13, 2022, $20M — THG Ventures, Lantian Capital
- Series A, Apr 19, 2019, $7.5M — Shenzhen Guozhong Venture Capital, Red Star Macalline Group Corporation, Wonderland Capital

## Investors

- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A
- Red Star Macalline Group Corporation — Series A
- Wonderland Capital — Series A
- THG Ventures (https://capitalatlas.ai/funds/thg-ventures) — Series A, Series C
- Lantian Capital (https://capitalatlas.ai/funds/lantian-capital) — Series A
- Taiping Guofa (https://capitalatlas.ai/funds/taiping-guofa) — Series B
- Shanghai Yungu Investment — Series B
- Wuhan Optical Valley Financial Holding Group — Series C